ARTMS develops and commercializes technologies and products that enable cyclotron production of medical radioisotopes. Its flagship QUANTM Irradiation System (QIS) and consumable products enable decentralized, cost-effective, large-scale production of isotopes including gallium-68, zirconium-89, technetium-99m and copper-64 using hospital and distributor cyclotrons. The company plans to develop and validate high-quality, high-activity zirconium-89 (Zr-89) for Immuno-PET to help identify patients likely to respond to immuno-oncology therapies. ARTMS will leverage its proprietary QIS hardware and solid-targetry expertise to produce Zr-89 for radiolabeling antibodies and other molecular targeting ligands. The work is intended to support decentralized, efficient radioisotope supply solutions and disrupt the current nuclear medicine supply chain. ARTMS is based in Vancouver, Canada. Artms develops the QUANTM Irradiation System (QIS), which enables decentralized, local production of medical isotopes including gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu). The QIS leverages locally based medical cyclotrons to allow users to control their supply chain and produce high volumes of radiopharmaceutical products. The company is led by CEO Charles S. Conroy and is based in Vancouver, British Columbia. Artms intends to continue collaborating with industry partners to develop cyclotron-produced 68Ga diagnostics. It also plans to expand commercialization of the QIS to produce additional critical medical isotopes. Financially, the company completed a Series A to support those commercialization and development efforts. ARTMS Products develops and commercializes the QUANTM Irradiation System (QIS), a hardware and consumable platform for cyclotron production of key medical isotopes including technetium-99m and gallium-68. The system enables decentralized, local isotope production for hospital-based use and has been installed and is operating in a number of countries. ARTMS says its platform produces no long-lived radioactive waste and advances efforts to eliminate the use of weapons-grade highly enriched uranium for Tc-99m production. The company is advancing commercialization of cyclotron-produced Ga-68 and plans to move new products into clinical development. ARTMS was developed in collaboration with TRIUMF and scientists at BC Cancer, the Centre for Probe Development and Commercialization, and Lawson Health Research. The company is based in Vancouver, British Columbia, and reports the funding will help increase revenue growth and create employment by advancing existing programs and building a second-generation QUANTM system. Artms Products, based in Vancouver, British Columbia, offers the QUANTM Irradiation System (QIS®), a hardware-and-consumable system that produces technetium-99m (Tc-99m) on medical cyclotrons. The company’s QIS addresses disruptions in global Tc-99m supply, an isotope used in over 80% of nuclear medicine imaging procedures. The technology was developed in collaboration with TRIUMF and scientists at three Canadian health research institutes, including the British Columbia Cancer Agency, the Centre for Probe Development and Commercialization, and Lawson Health Research. Early-stage research funding came from the Federal Government via NSERC and the Isotope Technology Acceleration Program (ITAP). Artms is led by CEO Dr. Paul Schaffer. The company plans to develop the QIS to enable production of other isotopes such as gallium-68, copper-64 and zirconium-89.

Total raised

$24M

Funding rounds

4

Latest round

Equity

Latest activity

Mar 2021